DISCLOSURES MANAGEMENT OF OPIOID USE DISORDERS LECTURE COVERS. SUDs ARE IMPORTANT. I have nothing to declare

Similar documents
Medication-Assisted Treatment. What Is It and Why Do We Use It?

Opioids Research to Practice

Substitution Therapy for Opioid Use Disorder The Role of Suboxone

Opioid Agonists. Natural derivatives of opium poppy - Opium - Morphine - Codeine

Prepared by: Dr. Elizabeth Woodward, University of Toronto Resident in Psychiatry

Opioids Research to Practice

ROSC & MAT II: Opioid Treatment Services

Medication Assisted Treatment. Karen Drexler, MD National Mental Health Program Director-Substance Use Disorders Department of Veterans Affairs

Medications in the Treatment of Opioid Use Disorder: Methadone and Buprenorphine What Really Are They?

Buprenorphine as a Treatment Option for Opioid Use Disorder

Opioids Research to Practice

Opioids Research to Practice

Opioids Research to Practice

Module II Opioids 101 Opiate Opioid

NORTHWEST AIDS EDUCATION AND TRAINING CENTER. Opioid Use Disorders. Joseph Merrill M.D., M.P.H. University of Washington April 10, 2014

Opioid dependence and buprenorphine treatment

7/7/2016 Journal of the American Medical Association,

THE MEDICAL MODEL: ADDICTION IS A BRAIN DISEASE. Judith Martin, MD Medical Director of Substance Use Services San Francisco Dept.

Opioids. October 29, Addiction Medicine Review Course CSAM, Newport Beach, CA

Opioid dependence: Detoxification

8/14/2017. Practical Approach to Office Based Addiction Treatment. Objectives. Foundation For Success Treating SUD

SW OREGON OPIOID SUMMIT. Medication Assisted Recovery for Opioid Use Disorder. Gregory S. Brigham, Ph.D. Adapt / SouthRiver CHC / Compass

Opioid Use in Youth. Amy Yule M.D. March 2,

Opioids- Indica-ons, Equivalence, Dependence and Withdrawal Methadone Maintenance (OST) Paul Glue

Medical Assisted Treatment of Opioid

Developed and Presented by Randall Webber, MPH, CADC JRW Behavioral Health Services

Methadone and Naltrexone ER

Main Questions. Why study addiction? Substance Use Disorders, Part 1 Alecia Schweinsburg, MA Abnromal Psychology, Fall Substance Use Disorders

Methadone and Naltrexone ER

The available evidence in the field of treatment of opiate: The experience of developing the WHO clinical guidelines

Admit date: 1-WM 2-WM 3.2-WM 3.7-WM 4-WM DSM-V diagnoses: Please list all diagnoses (psychiatric, chemical dependency and medical)

LONG TERM PHARMACOTHERAPY OF OPIOID DEPENDENCE

(Adapted with permission from the D-H Knowledge Map Primary Care Buprenorphine Guidelines)

Naltrexone Overview. Todd Korthuis, MD, MPH ECHO-MAT Conference November 7, 2017

Medication-Assisted Treatment (MAT) for Opioid Use Disorders

Opioid Replacement Therapy

Withdrawal.

GOALS AND OBJECTIVES

Buprenorphine is the most effective office-based treatment available for heroin and prescription opioid addiction

Buprenorphine for Family Medicine. Hannah Snyder, MD Addiction Medicine Fellow, UCSF 12/7/17

An overview of Medication Assisted Treatment (MAT) and acute pain management on MAT

PAIN & ANALGESIA. often accompanied by clinical depression. fibromyalgia, chronic fatigue, etc. COX 1, COX 2, and COX 3 (a variant of COX 1)

Mary Ann Ferguson,Pharmacist St Josephs Health Care Concurrent Disorders Inpatient Unit

Pharmacotherapy for Substance Use Disorders

Prescription Opioid Addiction

Recognizing Narcotic Abuse and Addiction and Helping Those With It

Overview of Opioid Use Disorder

Medication Assisted Treatment of Substance Use Disorders

Opioid Use Disorder Treatment Initiation in Diverse Settings

Pharmacotherapy for opioid addiction. Judith Martin, MD Medical Director BAART Turk Street Clinic San Francisco

WHAT CAN I EXPECT?: DUAL SUBSTANCE USE AND MENTAL HEALTH TREATMENT FOR MILITARY POPULATIONS

OPIOID SUBSTITUTION THERAPY RISKS & BENEFITS

Naltrexone Overview. Todd Korthuis, MD, MPH ECHO-MAT Conference February 14, 2017

Overview of Medication Assisted Treatment Methadone, Buprenorphine and Naltrexone

BAPTIST HEALTH SCHOOL OF NURSING NSG 3036A: PSYCHIATRIC-MENTAL HEALTH

Implementing Buprenorphine Treatment in Opioid Treatment Programs Webinar 2, October 3, 2018

4/5/2018 MEDICATION ASSISTED TREATMENT FOR OPIOID USE DISORDERS OBJECTIVES DEFINITION OF ADDICTION APRIL 11, 2018 RITU BHATNAGAR, M.D., M.P.H.

DSM-5 AND ASAM CRITERIA. Presented by Jaime Goffin, LCSW

Medication Assisted Treatment. MAT Opioid dependence/addiction Opioid treatment programs OTP Regulation of OTP Office Based Treatment

Serious Mental Illness and Opioid Use Disorder

Biological Addictions Treatment. Psychology 470. Many Types of Approaches

Perinatal, Neonatal, Pediatric Conference

ten questions you might have about tapering (and room for your own) an informational booklet for opioid pain treatment

Identification and Treatment of Opioid Use Disorders in Primary Care Settings

Pennsylvania Coordinated Medication Assisted Treatment: A Penn State and Pennsylvania Psychiatric Institute Story

Disclosure Statement. Learning Objectives. American Psychiatric Nurses Association. Christian J. Teter, PharmD, BCPP 1 BUPRENORPHINE UPDATE

Opioids. Sergio Hernandez, MD

NALTREXONE DAVID CRABTREE, MD, MPH UNIVERSITY OF UTAH HEALTH, 2018

Medical Assisted Treatment. Dr. Michael Baldinger Medical Director Haymarket Center Harborview Recovery Center

Medications for Opioid Use Disorder. Charles Brackett, MD, MPH General Internal Medicine, DHMC

Referral to Treatment: Utilizing the ASAM Criteria

HARM REDUCTION & TREATMENT. Devin Reaves MSW

Responding to the Opioid Epidemic

the facts about BUPRENORPHINE for Treatment of Opioid Addiction

Treatment of Opioid Use Disorder

Treatment of Opioid Use Disorder

Opioid Use Disorders &Medication Treatment

Building capacity for a CHC response to Ontario's Opioid Crisis

AN INTRODUCTION TO THE TREATMENT OF OPIOID USE DISORDERS IN PRIMARY CARE

9/13/2017. Buprenorphine Treatment (Suboxone) Disclosures. We ve Got a Big Opioid Problem. Selahattin Kurter, MD Spectrum Healthcare

MANAGING OPIOID WITHDRAWAL AND OPIOID USE DISORDER (OUD)

PART VI: TAPERING OPIOIDS ROBERT JENKINSON MD MARCH 7, 2018

AODA RECOVERY. How to support those in recovery, and those not yet ready to commit

THE STATE OF MEDICINE IN ADDICTION RECOVERY

Substance and Alcohol Related Disorders. Substance use Disorder Alcoholism Gambling Disorder

Wasted AN INTRODUCTION TO SUBSTANCE ABUSE

Vivitrol Vs. Suboxone

Opiate Use Disorder and Opiate Overdose

Latest Research on Addiction and Treatment

Buprenorphine pharmacology

Extended-Release Naltrexone for Opioid Relapse Prevention

Prescribing Framework for Naltrexone in Relapse Prevention (Opioid Dependence)

Trigger. Myths About the Use of Medication in Recovery BUPRENORPHINE TREATMENT: A TRAINING FOR MULTIDISCIPLINARY ADDICTION PROFESSIONALS

Buprenorphine and MAT 101

6/6/2018. Objectives. Outline. Rethinking Medication Treatment for Opioid Use Disorder

Medication-Assisted Treatment (MAT) Overview

The Social Worker s Role in Medication Assisted Treatment

Comorbidity of Substance Use Disorders and Psychiatric Conditions-2

Vivitrol/Suboxone. Comparison Study Summary

Psychosocial Treatments for Opioid Use Disorder Overview

Transcription:

MANAGEMENT OF OPIOID USE DISORDERS DISCLOSURES Marc A Schuckit Distinguished Professor of Psychiatry, UCSD Medical School I have nothing to declare SUDs ARE IMPORTANT Affect > 20% of your patients Are identified by non-experts Alcohol and drug use Rx responses Mimick most psychiatric Dx Deadly: opioid 33k ODs/yr Opoids cost US > $75 billion/yr LECTURE COVERS Drug groups & problems Substance use disorders Criteria Course After you re gone 1

LECTURE COVERS Drug groups & problems Substance use disorders Criteria Course After you re gone DRUG GROUPS Based on: Usual effects At usual doses Group then predicts: Pattern of problems DRUG GROUPS Depressants Hallucinogens Stimulants PCP THE GOOD, BAD, & UGLY Good pain, cough, shock, diarrhea euphoria, tranquility, sedation Opioids Cannabinols Solvents Others Bad Tolerance, craving, respirations Ugly: If opioid use disorder Is VERY hard to stop using 2

DRUG PROBLEMS LECTURE COVERS Drug groups & problems Overdose Withdrawal Delirium Psychosis Major depression Anxiety Substance use disorders Criteria Course After you re gone SUBSTANCE USE DISORDER In same year 2+ of: Failed roles Hazardous use Social problems Tolerance* Withdrawal* Use longer/more Unable to Lots time use activities Use despite probs Craving * Special re opioids SUD COURSE Fluctuating: Controlled use Problems Abstinence >20% spontaneous remission In richer & poorer Prevention: NEVER USE FOR A HIGH 3

LECTURE COVERS Drug groups & problems Substance use disorders Criteria Course After you re gone OVERDOSE Symptoms Awake respirations <12/min*/stupor*/miosis* Also: temp/ gut sounds/pulmonary edema Ventilate Naloxone: 0.04mg IM, IN, IV but not oral If no respiration in 2 min 0.5mg 2mg 5mg 10mg 15mg Yes YES O 2 Naloxone ICU Long Acting Opioid? Continuous IV Naloxone ± Intubate Observe 6hr ~ p IV stop Opioid OD Decisions Resp < 12min when awake NO NO Observe 6hr ~ p last naloxone NO ICU Awake/alert NO Long Acting Opioid? Yes Refer for OP Rx Yes Observe 8+hr STAGES OF RX : drop stereotypes Physical exam & history Enhance motivation Help readjust to life Aftercare Reassurance Relapse prevention Boyer NEJM 2012 4

TO ID: ASK ABOUT PROBLEMS QUESTIONNAIRES Relationships School or job Accidents Legal Health CAGE-AID (2+): Feel need cut down Feel bad or guilty Annoyed by criticisms Eye-opener for relief/steady Drug Use Questionnaire (DAST-10: 3+) Then tie in substances Non-med use/multi drugs/not stop/blackout/guilt/ Complaints/neglect/illegal/withdrawal/med probs MOTIVATIONAL INTERVIEWING Build trust Empathic Avoid resistance Patient is in charge Elicit motivational statements Explore ambivalence Monitor readiness to change STAGES OF RX Physical exam & history Vitamins Enhance motivation Help readjust to life Aftercare Reassurance Relapse prevention 5

Depressants Opioids DETOX Stimulants (no specific Rx) DETOX RX Physical exam Rest & education Nutrition Meds for: Opioids KEY MEDICATIONS Methadone (oral): Mu-opioid agonist; ½ life 15-20 hrs Buprenorphine (SL or buccal) Partial mu agonist; kappa antagonist ½ life 3 hrs (longer recepter occupation) Mu antagonists: Naltrexone ½ life: oral 4-13 hrs IM 5-10 days Naloxone (not oral): onset 2 min; action 20-90 min OPIOID WITHDRAWAL Symptoms opposite of acute effects Timing depends on drug length action PE, educate, motivate Methadone or Buprenorphene 6

CLINICAL OPIOID WITHDRAWAL SCALE (COWS) Pulse > 80 Rhinorrhea Sweating Cramps/naus/vomit Restless Tremor Pupils Yawning Bone/joint pain Anxous/irritable Goosebumps Each scored 1-4 or 1-5 Total: 5-12 = mild 25-36 = mod/severe 13-24 = mod > 36 = severe WITHDRAWAL Detox rehabilitation Onset symptoms Naloxone: in 2 minutes Short acting (heroin): ~ 8 hrs, day 4 Long acting (methadone): 1+ days, day 10 Protracted withdrawal: 2 weeks to 2+ months Fatigue appetite insomnia anhedonia LONG ACTING OPIOID TAPER Oral methadone SL buprenorphine PE PE: Rx at mild sympt Initial dose (ck in 1 hr; adjust) 10 mg < current dose 4-8 mg 10-30 mg/d ( ) Stabilize 7-14 days 2-5 days Taper ~ 0-20% of initial dose Every 1-2 days OPIOID-FREE DETOX Med Dose Target Clonidine 0.1-0.2mg q 4h Flu-like patch 1 for 100-200 # Diazepam 2-10mg q 4h Insom/anxiety Imodium 4mg, then 2mg Diarrhea Naproxin 500mg 2x/d Aches/pain Compazine 5-10mg q 4h Naus/vomit 7

STAGES OF RX Physical exam & history Vitamins Reassurance REHABILITATION Increase motivation Help rebuild life Enhance motivation Help readjust to life Aftercare Relapse prevention Relapse prevention +/- medications Action: REHAB: NALTREXONE Restriction: Induction: Blocks opioid high/ craving Must be opioid free Test : 12.5mg; in 4 h 25-50mg Day 1: Begin 50-100mg/d Maintenance: 100mg Mon & Wed 150mg Fri OR 380mg IM/mo MAINTENANCE GOALS Substitute safer opioid Oral to avoid craving set on by needles Long acting to avoid daytime symptoms Use 1+ years note OD danger when stop Rx includes counseling pain control monitoring Goals: IV dangers Health Crime Work OD Relationships 8

Action: REHAB:METHADONE Oral & long ½ life opioid REHAB: BUPRINORPHINE Action: SL/buccal long ½ life opioid & naloxone (4 to 1 ratio) Restriction: Only in special clinics Restriction: Trained pvt doc office OK Induction: 1-2 wk:15-30mg 10-50mg ~q 5d to 50-100mg Induction: Wk 1-8: 4-8mg/d up to 16-32mg Maintenance: Consider take-home weekend dose if adherent to Rx at 8 wk Maintenance: Dose on SE and craving CBT dysfunctional thoughts (must have drugs) rational thoughts (I can change) Relapse prevention (risk never ends) Anticipate triggers Learn to cope w/triggers Change behaviors (sober friends; stress) 9